Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04546581 · ClinicalTrials.gov registry record · Phase 3
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
A Phase 3 study of COVID-19 and SARS-CoV-2, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 3
- Development phase
- 593
- Enrollment target
- 20
- Study locations
NCT04546581 is a Phase 3 study of COVID-19 and SARS-CoV-2 that has completed, run by University of Minnesota. The registered enrollment target is 593 participants, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04546581, a Phase 3 study of COVID-19 and SARS-CoV-2, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 593 participants
- Enrollment target
- 20
- Study locations
Study Summary
This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials will involve sites around the world strategically chosen to ensure rapid enrollment. This trial will compare hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo, when added to standard of care (SOC), for preventing further disease progression and mortality related to COVID-19. SOC will include remdesivir unless it is contraindicated for an individual patient.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Remdesivir
- BIOLOGICAL Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Study Locations (20)
Colorado
- Penrose Hospital - Colorado Springs
- St. Francis Health Services - Colorado Springs
- St. Anthony Hospital - Lakewood
- Saint Anthony North Health Campus - Westminster
Texas
- Hendrick Medical Center - Abilene
- CHRISTUS Spohn Shoreline Hospital - Corpus Christi
- University of Texas Southwestern Medical Center - Dallas
Missouri
- University of Missouri - Columbia
- Cox Medical Centers - Springfield
Virginia
- CJW Chippenham Medical Center - Richmond
- Henrico Doctors' Hospital (HCA) - Richmond
Other
- Aarhus Universitetshospital, Skejby - Aarhus
- Bispebjerg Hospital - Copenhagen
District of Columbia
- Washington VA Medical Center - Washington D.C.
Georgia
- Redmond Regional Medical Center - Rome
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 593 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2021-05-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04546581
The ClinicalTrials.gov registry entry for NCT04546581 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 593 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04546581 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Colorado, Texas, Missouri.
Frequently Asked Questions
What is clinical trial NCT04546581 about?
NCT04546581 is a clinical study titled "Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)". This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials will involve sites around the world strategically chosen to ensure rapid enrollment. This trial will compare hyperimmun...
What is the current status of trial NCT04546581?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 593 participants. The study started on 2020-10-08. Estimated completion is 2021-05-21.
What conditions does trial NCT04546581 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2, COVID, SARS (Severe Acute Respiratory Syndrome).
What interventions are being tested in trial NCT04546581?
The interventions under investigation include: Placebo (OTHER), Remdesivir (DRUG), Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04546581?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04546581 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.